Neurogene Inc. (NGNE)
$36.58-$1.28 (-3.38%) Today
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 5 | 9,600 | $340K |
| Grant or award | 1 | 15,400 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
24 Form 4 filings on record, the earliest from Nov 26, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 600 | $36.02 | $22K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,200 | $36.13 | $152K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 739 | $34.06 | $25K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 2,531 | $34.58 | $88K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 1,530 | $35.23 | $54K | |
| Keith Woods - Director | Grant or award | Stock Option (Right to Buy) | 15,400 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,800 | $30.07 | $144K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,800 | $32.44 | $156K | |
 Christina Shafer - Officer | Grant or award | Non-Qualified Stock Option (right to buy) | 120,000 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 2,558 | $21.62 | $55K | |
| Rachel McMinn - Officer | Open-market sale | Common Stock | 3,352 | $22.07 | $74K | |
 Julie Jordan - Officer | Open-market sale | Common Stock | 828 | $21.89 | $18K | |
| Stuart Cobb - Officer | Open-market sale | Common Stock | 148 | $22.08 | $3K | |
| Stuart Cobb - Officer | Open-market sale | Common Stock | 3,991 | $20.41 | $81K | |
| Stuart Cobb - Officer | Open-market sale | Common Stock | 2,658 | $21.34 | $57K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 263 | $22.02 | $6K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 2,387 | $20.42 | $49K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 1,395 | $21.25 | $30K | |
| Christine Mikail Cvijic - Officer | Open-market sale | Common Stock | 4,800 | $25.11 | $121K | |
| Stuart Cobb - Officer | Grant or award | Common Stock | 16,500 | $0.00 | - | |
| Julie Jordan - Officer | Grant or award | Common Stock | 4,900 | $0.00 | - | |
| Julie Jordan - Officer | Grant or award | Stock Option (Right to Buy) | 29,600 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Grant or award | Common Stock | 22,000 | $0.00 | - | |
| Christine Mikail Cvijic - Officer | Grant or award | Stock Option (Right to Buy) | 131,900 | $0.00 | - | |
| Rachel McMinn - Officer | Grant or award | Common Stock | 25,900 | $0.00 | - | |
| Rachel McMinn - Officer | Grant or award | Stock Option (Right to Buy) | 155,100 | $0.00 | - | |
 Rohan Palekar - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Robert Baffi - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Sarah B. Noonberg - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Cory S. Freedland - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Keith Woods - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Robert Baffi - Director | Grant or award | Non-Qualified Stock Option (right to buy) | 12,050 | $0.00 | - | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 20,748 | $24.91 | $517K | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 10,803 | $26.01 | $281K | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 15,219 | $26.73 | $407K | |
| Samsara BioCapital GP, LLC | Open-market purchase | Common Stock | 2,000 | $27.50 | $55K | |
| Christine Mikail Cvijic - Officer | Open-market purchase | Common Stock | 24,000 | $20.48 | $491K | |
| Rachel McMinn - Officer | Open-market purchase | Common Stock | 47,500 | $20.40 | $969K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR |
Neurogene Inc. (NGNE) had 3 insider filings in the last 90 days, with the most recent on 2026-07-08. The full record for NGNE runs to 24 Form 4 filings, the earliest from 2024-11-26. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of NGNE were filed in the last 90 days. 6 purchases are on record for this company.
5 insider sales of NGNE were filed in the last 90 days, totaling $340K.
This page tracks NGNE Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NGNE to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
